Stock News

The Comprehensive Analysis of GBDC’s Dividend Sustainability Metrics Introduction In the world of Business Development Companies (BDCs), dividend sustainability is a key factor that investors often evaluate. In this article, we will delve into Garrison Capital Inc. (GBDC) and compare its recent dividend per share rates, yield percentages, and other crucial dividend sustainability metrics to…

Embracing Change: Understanding Securities Repurchasing Programs Introduction As we navigate through the complex world of finance and investing, it’s essential to stay informed about the latest developments and trends. One such trend is securities repurchasing programs, which have recently gained traction in the market. Today, we’ll delve into the specifics of a recent securities repurchasing…

Dupixent Phase 3 Study Confirms Significant Improvements in Itch and Hives for Patients with CSU Paris and Tarrytown, NY, September 11, 2024. A Dupixent (dupilumab) confirmatory phase 3 study (LIBERTY-CUPID Study C) met the primary and key secondary endpoints for the investigational treatment of patients with uncontrolled, biologic-naïve CSU receiving background therapy with antihistamines. Confirming…

Dupixent Achieves Breakthrough Results in Pivotal Study for Bullous Pemphigoid Treatment Significant Improvements in Disease Remission Dupixent has made history as the first and only biologic to achieve significant improvements in disease remission and symptoms in a pivotal study focused on bullous pemphigoid. The study, known as ADEPT, demonstrated that Dupixent met the primary endpoint…

GameStop’s Revenue Takes a Dive, but Earnings Look Up What’s Going on with GameStop? It’s been a rollercoaster ride for GameStop in Q2 of 2024. The company’s revenue fell a whopping 31.4%, missing expectations, but surprisingly, earnings exceeded forecasts. This paints a picture of a company that’s struggling to bring in sales, but managing to…

Terns Pharmaceuticals, Inc. Announces Pricing of Public Offering Introduction Terns Pharmaceuticals, Inc. has recently made headlines with the announcement of the pricing of its upsized underwritten public offering. The clinical-stage biopharmaceutical company is focused on developing small-molecule product candidates to tackle serious diseases, including oncology and obesity. This latest development is set to have a…

Are You Ready to Take Action? Act Fast or Miss Out! Don’t Let Opportunity Slip Away Hey there, savvy investors! Have you heard about the latest opportunity to potentially recoup losses in the stock market? If not, don’t worry – we’ve got you covered. Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney…

Welcome to the World of Biopharmaceuticals! An Exciting Announcement from Innovent Biologics SAN FRANCISCO and SUZHOU, China, Sept. 10, 2024 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801) has recently made waves in the biopharmaceutical world with the presentation of Phase 1 clinical data for their groundbreaking IBI363 drug. IBI363 is a first-in-class PD-1/IL-2α-bias bispecific…